Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-10-09
2008-12-16
Hartley, Michael G. (Department: 1618)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S335000
Reexamination Certificate
active
07465803
ABSTRACT:
Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X1-L-(W)p—NO2wherein A contains the radical of a drug, X1and W are bivalent radicals, p is an integer equal to 1 or 0, and L is a covalent bond, CO, oxygen, sulphur, or NR1Cwhere R1Cis H or a C1-C5linear or branched alkyl.
REFERENCES:
patent: 4721709 (1988-01-01), Seth et al.
patent: 5859053 (1999-01-01), Lesur et al.
patent: 5861426 (1999-01-01), Del Soldato et al.
patent: 6040341 (2000-03-01), Del Soldato et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6538033 (2003-03-01), Bing
patent: 2002/0187536 (2002-12-01), Kulkarni et al.
patent: 0 722 434 (1996-07-01), None
patent: 0 738 706 (1996-10-01), None
patent: 94/04484 (1994-03-01), None
patent: 94/12463 (1994-06-01), None
patent: 95/09831 (1995-04-01), None
patent: 95/30641 (1995-11-01), None
patent: WO 96/34848 (1996-11-01), None
patent: WO 98/09948 (1998-03-01), None
patent: 99/27912 (1999-06-01), None
patent: 99/27913 (1999-06-01), None
patent: 00 44705 (2000-08-01), None
patent: 00 51988 (2000-09-01), None
patent: 00 61541 (2000-10-01), None
patent: WO 00/61537 (2000-10-01), None
patent: 00/77838 (2000-12-01), None
patent: 01 00563 (2001-01-01), None
patent: 01 04082 (2001-01-01), None
patent: 01 012584 (2001-02-01), None
patent: 01/66087 (2001-09-01), None
patent: 01/66088 (2001-09-01), None
patent: 03/022249 (2003-03-01), None
patent: 03/080029 (2003-10-01), None
patent: 2004/026808 (2004-04-01), None
The W. Greene, “Protective groups in organic synthesis,” Harvard University Press, 1980.
Remington's Pharmaceutical Sciences, 15th Ed., 1975.
“Synthesis and Stability of 2-Methyl-2,4-diaza- and 2-Methyl-2,5-diaza-indene + (2-Methyl-pyrrolo[3,4-b] pyridine and -pyrrolo[3,4-c]pyridine),” J. Chem. Soc., Perkin Trans. 1, 1972, vol. 20, pp. 2485-2490.
“A T cell-dependent experimental liver injury in mice induced by Concanavalin A.,” Tiegs G., Hentshel J., A. Wendel, J. Clin. Invest., Jul. 1992, vol. 90, pp. 196-203.
“EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells,” Turner T., Chen, P., Goodly L. J., Wells A., Clinical & Experimental Metastasis 1996, vol. 14, No. 4, pp. 409-418.
Gordon L. Amidon et al., “A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability,” Pharmaceutical Research, vol. 12, No. 3, 1995, pp. 413-420.
Richard J. Bing et al., “The Pharmacology of a New Nitric Oxide Donor: B-NOD,” Biochemical and Biophysical Research Communications 275, 2000, pp. 350-353.
Carmela De Santo et al., “Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination,” PNAS, vol. 102, No. 11, Mar. 15, 2005, pp. 4185-4190.
F. Fabbri et al., “Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells,” Apoptosis, vol. 10, No. 5, 2005, pp. 1095-1103.
Jianjun Gao et al., “In Vitro Metabolism of Nitric Oxide-Donating Aspirin: The Effect of Positional Isomerism,” The Journal of Pharmacology and Experimental Therapeutics, vol. 312, No. 3, 2005, pp. 989-997.
Sandra Huguenin et al., “Nitrosulindac (NCX 1102): A New Nitric Oxide-Donating Non-Steroidal Anti-Inflammatory Drug (NO-NSAID), Inhibits Proliferation and Induces Apoptosis in Human Prostatic Epithelial Cell Lines,” Wiley InterScience, Mar. 16, 2004, pp. 132-141.
Sandra Huguenin et al., “Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines,” Cancer Letters 218, 2005, pp. 163-170.
Sandra Huguenin et al., “Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder cancinoma cell lines,” Molecular Cancer Therapeutics, 2003, pp. 291-298.
Khosrow Kashfi et al., “Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention,” Biochemical Pharmacology 70, 2005, pp. 969-986.
Khosrow Kashfi et al., “Positional Isomerism Markedly Affects the Growth Inhibition of Colon Cancer Cells by Nitric Oxide-Donating Aspirin in Vitro and in Vivo,” The Journal of Pharmacology and Experimental Therapeutics, vol. 312, No. 3., 2005, pp. 978-988.
Khosrow Kashfi et al., “Nitric Oxide-Donating Nonsteroidal Anti-Inflammatory Drugs Inhibit the Growth of Various Cultured Human Cancer Cells: Evidence of a Tissue Type-Independent Effect,” The Journal of Pharmacology and Experimental Therapeutics, vol. 303, No. 3, 2002, pp. 1273-1282.
Christian Lavagna et al., “Antiproliferative Effects of Nitrosulindac on Human Colon Adenocarcinoma Cell Lines,” Biochemical and Biophysical Research Communications, vol. 284, No. 3, 2001, pp. 808-816.
Niharika Nath et al., “NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression,” Biochemical and Biophysical Research Communications 326, 2005, pp. 93-99.
Niharika Nath et al., “Nitric oxide-donating aspirin inhibits β-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association,” PNAS, vol. 100, No. 22, Oct. 28, 2003, pp. 12584-12589.
B. Rigas et al., “NO-SAIDs and cancer: promising novel agents,” Digestive and Liver Disease 35 (Suppl. 2), 2003, pp. S27-S34.
B. Rigas et al., “Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction,” Medical Hypotheses 54(2), 2000, pp. 210-215.
Basil Rigas et al., “NO-releasing NSAIDs and colon cancer chemoprevention: A promising novel approach (Review),” International Journal of Oncology 20, 2002, pp. 885-890.
Basil Rigas et al., “Nitric-oxide-donating NSAIDs as agent for cancer prevention,” Trends in Molecular Medicine, vol. 10, No. 7, Jul. 2004, pp. 324-330.
Basil Rigas et al., “Cancer Prevention: A New Era beyond Cyclooxygenase-2,” The Journal of Pharmacology and Experimental Therapeutics, vol. 314, No. 1, 2005, pp. 1-8.
Justine Sarah Royle et al., “Nitric Oxide Donating Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Human Prostate Cancer Cell Systems and Human Prostatic Stroma Via Caspase-3,” The Journal of Urology, vol. 172, Jul. 2004, pp. 338-344.
Adam Spiegel et al., “NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells,” Biochemical Pharmacology 70, 2005, pp. 993-1000.
Anna Tesei et al., “NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines,” International Journal of Oncology 22, 2003, pp. 1297-1302.
Anna Tesei et al., “In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines,” Journal of Translational Medicine 2005, 3:7, pp. 1-12.
Jennie L. Williams et al., “Nitric Oxide-releasing Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Alter the Kinetics of Human Colon Cancer Cell Lines More Effectively than Traditional NSAIDs: Implications for Colon Cancer Chemoprevention,” Cancer Research 61, Apr. 15, 2001, pp. 3285-3289.
Jennie L. Williams et al., “NO-donating aspirin inhibits intestinal carcinogenesis inMin(APCMinl+) mice,” Biochemical and Biophysical Research Communications 313, 2004, pp. 784-788.
Jennie L. Williams et al., “Growth Inhibition of Human Colon Cancer Cells by Nitric Oxide (NO)-Donating Aspirin Is Associated with Cyclooxygenase-2 Induction and β-Catenin/T-Cell Factor Signaling, Nuc
Antognazza Patrizia
Benedini Francesca
Del Soldato Piero
Arent & Fox LLP
Gembeh Shirley V
Hartley Michael G.
Nicox S.A.
LandOfFree
Nitroderivatives as drugs for diseases having an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitroderivatives as drugs for diseases having an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitroderivatives as drugs for diseases having an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4020921